Search

Your search keyword '"Nannini EC"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Nannini EC" Remove constraint Author: "Nannini EC"
35 results on '"Nannini EC"'

Search Results

1. Characteristics of endemic human coronavirus infections during times of COVID-19 pandemic.

2. Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma.

3. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

4. [Impact of population mobility on the behavior of respiratory viruses during the COVID-19 pandemic].

5. Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19.

6. Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19.

7. Ceftaroline as salvage therapy for methicillin susceptible Staphylococcus aureus complicated bacteremia.

8. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.

9. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.

10. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.

11. Polyclonal outbreak of bacteremia caused by Burkholderia cepacia complex and the presumptive role of ultrasound gel.

12. Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals.

13. In Vivo Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against Cefazolin.

15. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.

16. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

17. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus.

18. Ceftaroline for complicated skin and skin-structure infections.

19. Telavancin's interactions with the bacterial cell membrane.

20. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure.

21. A new lipoglycopeptide: telavancin.

23. Decreased virulence of a gls24 mutant of Enterococcus faecalis OG1RF in an experimental endocarditis model.

24. Fsr-independent production of protease(s) may explain the lack of attenuation of an Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis.

25. Importance of gls24 in virulence and stress response of Enterococcus faecalis and use of the Gls24 protein as a possible immunotherapy target.

26. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.

27. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue.

28. Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature.

29. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.

30. HIV1 and the gut in the era of highly active antiretroviral therapy.

31. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.

32. Genotypic HIV-1 drug resistance testing in antiretroviral-naive subjects in Houston, Texas.

33. Jejunal cytokine response in AIDS patients with chronic cryptosporidiosis and during immune reconstitution.

Catalog

Books, media, physical & digital resources